PriceTargets.com logo

Galectin Therapeutics - GALT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 225.44%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.38 As of 04/18/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for GALT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Galectin Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GALT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GALT

Analyst Price Target is $11.00
▲ +225.44% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Galectin Therapeutics in the last 3 months. The average price target is $11.00, with a high forecast of $11.00 and a low forecast of $11.00. The average price target represents a 225.44% upside from the last price of $3.38.

This chart shows the closing price for GALT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Galectin Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
4/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00Low
3/3/2023HC WainwrightReiterated RatingBuy$11.00Low
5/17/2022HC WainwrightLower TargetBuy$14.00 ➝ $11.00N/A
4/1/2022HC WainwrightReiterated RatingBuyLow
4/16/2021HC WainwrightBoost TargetBuy$12.00 ➝ $14.00Low
8/13/2020HC WainwrightBoost TargetBuy$9.00 ➝ $12.00High
4/3/2020B. RileyReiterated RatingBuy$8.00 ➝ $4.00Medium
3/17/2020HC WainwrightLower TargetBuy$11.00 ➝ $9.00High
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 6 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 6 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Galectin Therapeutics logo
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Read More

Today's Range

Now: $3.38
Low: $3.25
High: $3.45

50 Day Range

MA: $2.41
Low: $1.66
High: $4.20

52 Week Range

Now: $3.38
Low: $1.28
High: $4.27

Volume

146,616 shs

Average Volume

125,164 shs

Market Capitalization

$209.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Galectin Therapeutics?

The following equities research analysts have issued reports on Galectin Therapeutics in the last year: HC Wainwright, and StockNews.com.
View the latest analyst ratings for GALT.

What is the current price target for Galectin Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Galectin Therapeutics in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 225.4%. HC Wainwright has the highest price target set, predicting GALT will reach $11.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $11.00 for Galectin Therapeutics in the next year.
View the latest price targets for GALT.

What is the current consensus analyst rating for Galectin Therapeutics?

Galectin Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GALT will outperform the market and that investors should add to their positions of Galectin Therapeutics.
View the latest ratings for GALT.

What other companies compete with Galectin Therapeutics?

Other companies that are similar to Galectin Therapeutics include Silverback Therapeutics, Abeona Therapeutics, Design Therapeutics, Generation Bio and G1 Therapeutics. Learn More about companies similar to Galectin Therapeutics.

How do I contact Galectin Therapeutics' investor relations team?

Galectin Therapeutics' physical mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company's listed phone number is (678) 620-3186 and its investor relations email address is [email protected]. The official website for Galectin Therapeutics is www.galectintherapeutics.com. Learn More about contacing Galectin Therapeutics investor relations.